LAS VEGAS, June 25, 2020
"Growth of ALL market is expected to be driven by rising incident cases of ALL, steady uptake of approved and emerging therapies along with an expected increase in investment in the R&D activities. CAR-T cell therapies are expected to dominate the Acute lymphoblastic leukemia market as five of the immunotherapies in the pipeline are geared up to enter the market by 2023."
LAS VEGAS, June 25, 2020 /PRNewswire/ -- DelveInsight has announced the expansion of the forecast period to 2020-2030 for its report on 'Acute Lymphoblastic Leukemia (ALL) Market Insight, Epidemiology and Market Forecast -2030'.
Request for Free Sample Pages of the Report: https://www.delveinsight.com/sample-request/acute-lymphoblastic-leukemia-all-market
Acute lymphocytic leukemia (ALL), also known as acute lymphoblastic leukemia, is a type of cancer that affects the blood and bone marrow. The tumor begins from young white blood cells known as lymphocytes in the bone marrow; mainly characterized by the production of immature white blood cells, called lymphoblasts or leukemic blasts in excess. ALL is caused by a lack of normal circulating blood cells. The exact causes of acute lymphocytic leukemia remain mostly unknown; still, it is thought to result from mutations in one or more of the genes that usually control blood cell development. This mutation will result in abnormal growth. It is mainly classified into B-cell and T-cell ALL. ALL can occur at any age but is more common in young children (0–14 years), and it develops quickly, so people are usually only unwell for only a short period before they are diagnosed.
Acute lymphocytic leukemia, an uncommon cancer of the blood, had a total incidence of 10,341 in the 7MM in 2017. The ALL incidence is expected to further rise during the forecast period 2020-2030. The US accounted for approximately 50% of the total Acute lymphocytic leukemia incident population in the 7MM. Among EU5 countries, Germany topped the list of highest ALL incident cases, with France following behind. Spain accounted for the least ALL incidence among all the 7MM countries.
The Acute lymphocytic leukemia epidemiological analysis demonstrated a higher male preponderance, and approximately 56% of the affected population belonged to the age group <20 years.
DelveInsight's Acute lymphocytic leukemia epidemiological segment of the report provides historical as well as forecasted trends for the period 2020-30 bifurcating the patient pool into
The Acute lymphocytic leukemia treatment options include Chemotherapy, Post Remission Therapy (Consolidation and Maintenance Therapy), Targeted Therapy, Immunotherapy, and CAR-T cell therapy. Stem Cell Transplant is also an alternative for the patients who are at early stages of treatment with high-risk subtypes of ALL.
However, Immunotherapy offers a broad and promising approach to cure cancer using the body's immune system. After the first-ever FDA approval to CAR-T cell therapy Kymriah (Tisangenlecleucel; Novartis) for the treatment of ALL, several advances in the clinical setting have been made, leading to more effective treatment strategies. As of 2020, Targeted immunotherapy drugs are available to address the relapsed or refractory Acute lymphocytic leukemia cases and are a favorable option for the treatment of older patients within clinical practice. However, there is a significant requirement to develop appropriate strategies for adolescents and young adult ALL patients, which fall between the standard categories of paediatric or adult ALL.
Acute lymphocytic leukemia Marketed Therapies
Present Acute lymphocytic leukemia market scenario is enriched with several companies evaluating novel drug molecules and targets as well as finding ways to add to the efficacy of existing ALL treatment approaches. DelveInsight estimates that Blincyto with its broader indication approval shall be at an early mover advantage to other lines of settings and is expected to dominate the second-line setting as well. However, it would be met by stiff competition from Besponsa and Kymriah.
The Acute lymphocytic leukemia pipeline hosts CAR-T cell therapies including KTE-X19 (Gilead Sciences), AUTO1 (Autolus Limited), PBCAR0191 (Precision BioSciences/Servier), UCART19 (Servier/Allogene), and Lisocabtagene Maraleucel/JCAR017 (Bristol-Myers Squibb), which are the major factors providing momentum to the Acute lymphocytic leukemia market.
Acute lymphocytic leukemia Pipeline Therapies
The dynamics of the overall Acute lymphocytic leukemia market is anticipated to shift positively during the forecast period 2020-30 attributable to rising ALL incidence, improvement in the rise in the number of healthcare spending across the world, a shifted focus to targeted immunotherapies and heightened interest of the major pharma and biotech players. However, there exist barriers that are expected to slow down the growth of ALL market as well. Due to the fact that it is uncommon cancer, there is difficulty in the recruitment of patients into clinical trials. Moreover, the cost of immunotherapies has always been questioned as most of the times, they are unaffordable. The entry of generics such as Sprycel (dasatinib) is another speed-breaker reducing the speed of the growth of the Acute lymphocytic leukemia market.
Identify Key Trends of Acute lymphocytic leukemia Market: https://www.delveinsight.com/report-store/acute-lymphoblastic-leukemia-all-market
Scope of the Report
Reason to purchase
Table of Contents
Executive Summary of Acute lymphocytic leukemia
SWOT Analysis of Acute lymphocytic leukemia
Acute lymphocytic leukemia Market Overview at a Glance
Acute lymphocytic leukemia: Disease Background and Overview
Acute lymphocytic leukemia Diagnosis
Acute lymphocytic leukemia Epidemiology and Patient Population
The United States Acute lymphocytic leukemia Epidemiology
EU-5 Country-wise Acute lymphocytic leukemia Epidemiology
Japan Acute lymphocytic leukemia Epidemiology
Current Acute lymphocytic leukemia Treatment Practices
Acute lymphocytic leukemia Treatment Algorithms
Acute lymphocytic leukemia Guideline
Unmet Needs in Acute lymphocytic leukemia Market
Acute lymphocytic leukemia: Patient Journey
Key Endpoints in Acute lymphocytic leukemia Clinical Trials
Acute lymphocytic leukemia Marketed Therapies
Emerging Acute lymphocytic leukemia Therapies
Conjoint Analysis of Acute lymphocytic leukemia
Acute lymphocytic leukemia: Seven Major Market Analysis
7MM Acute lymphocytic leukemia Market Size
United States Acute lymphocytic leukemia Market Size
EU-5 Acute lymphocytic leukemia Market Size
Japan Acute lymphocytic leukemia Market Size
Market Access and Reimbursement of Acute lymphocytic leukemia Therapies
Acute lymphocytic leukemia Market Drivers
Acute lymphocytic leukemia Market Barriers
Request a WebEx Walkthrough of the Report: https://www.delveinsight.com/report-store/acute-lymphoblastic-leukemia-all-market
Acute Lymphoblastic Leukemia (ALL) - Pipeline Insights, 2020
"Acute Lymphoblastic Leukemia Pipeline " report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Acute Lymphoblastic Leukemia market. A detailed picture of the Acute Lymphoblastic Leukemia (ALL) pipeline landscape is provided, which includes the disease overview and Acute Lymphoblastic Leukemia (ALL) treatment guidelines.
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia (ALL)- Market Insights and Market Forecast- 2030
DelveInsight's "CAR T-Cell Therapy for Acute Lymphoblastic Leukemia " report delivers an in-depth understanding of the CAR T-Cell Therapy use for Acute Lymphoblastic Leukemia as well as the CAR T-Cell Therapy market trends for Acute Lymphoblastic Leukemia in the 6MM, i.e., United States and EU5 (Germany, Spain, Italy, France and the United Kingdom).
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.